D. Medical Consummates the Sale of its Holdings in its Publicly Held Subsidiary, NextGen Biomed Ltd.
(firmenpresse) - TIRAT CARMEL, ISRAEL -- (Marketwire) -- 08/03/11 -- D. Medical Industries Ltd. (NASDAQ: DMED)(TASE: DMED) ("D. Medical" or the "Company"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, announced today the closing of the sale of its holdings in its publicly held subsidiary, NextGen Biomed Ltd. for a total consideration, following closing adjustments, of NIS 5.5 Million (approximately US$1.6 Million).
About D. Medical
D. Medical is a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery. D. Medical has developed durable and semi-disposable insulin pumps, which continuously infuse insulin into a patient's body, using its proprietary spring-based delivery technology. D. Medical believes that its spring-based delivery mechanism is cost-effective compared to the motor and gear train mechanisms that drive competitive insulin pumps and also allows it to incorporate certain advantageous functions and design features in its insulin pumps. D. Medical has also developed an infusion set for insulin pumps and is focusing its research and development efforts on the development of next generation insulin pumps and a device that will combine a continuous glucose monitoring system and an insulin pump on the same patch. For more information, please visit (corporate) and http://www.springnow.com (healthcare professionals, patients and care givers).
Forward-Looking Statements
This press release contains forward-looking statements (as defined by the Israeli Securities Law, 1968, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended) that involve risks and uncertainties. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or of any of them will transpire or occur, what impact it will have on D. Medical's results of operations or financial condition. D. Medical does not undertake to update any forward-looking statements.
Contacts:
D. Medical Industries LTD
Amir Loberman
Chief Financial Officer
+972-73-2507135
North American Investor Contact:
Stephen Kilmer
212-618-6347
Israeli Investor Relations:
Iris Lubitch
+972-775538007
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 03.08.2011 - 06:06 Uhr
Sprache: Deutsch
News-ID 1027019
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
TIRAT CARMEL, ISRAEL
Phone:
Kategorie:
Medical Devices
Anmerkungen:
Diese Pressemitteilung wurde bisher 232 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"D. Medical Consummates the Sale of its Holdings in its Publicly Held Subsidiary, NextGen Biomed Ltd.
"
steht unter der journalistisch-redaktionellen Verantwortung von
D. Medical Industries Ltd. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
